(+/-)-5-(6-AMINO-9H-PURIN-9-YL)-1-[PHOSPHORYLOXYMETHYL]-BICYCLO-[3.1.0]-HEXANE-2,3-DIOL
Compound with spectra: 1 NMR
![(+/-)-5-(6-AMINO-9H-PURIN-9-YL)-1-[PHOSPHORYLOXYMETHYL]-BICYCLO-[3.1.0]-HEXANE-2,3-DIOL](/api/compound/GjKWhNfrsD0.png?ph=true&h=300&w=458 "(+/-)-5-(6-AMINO-9H-PURIN-9-YL)-1-[PHOSPHORYLOXYMETHYL]-BICYCLO-[3.1.0]-HEXANE-2,3-DIOL")
| SpectraBase Compound ID | GjKWhNfrsD0 |
|---|---|
| InChI | InChI=1S/C12H16N5O6P/c13-10-7-11(15-3-14-10)17(4-16-7)12-1-6(12)5(8(18)9(12)19)2-23-24(20,21)22/h3-6,8-9,18-19H,1-2H2,(H2,13,14,15)(H2,20,21,22)/t5-,6-,8+,9+,12+/m1/s1 |
| InChIKey | DSJWBZWMSATVRM-ANBGNZKNSA-N |
| Mol Weight | 357.26 g/mol |
| Molecular Formula | C12H16N5O6P |
| Exact Mass | 357.08382 g/mol |
| Enantiomer InChIKey | DSJWBZWMSATVRM-QRSDYGCRSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | D2O |
benzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine, 3-(1,3-benzodioxol-5-yl)-8,9,10,11-tetrahydro-10-methyl-
(E)-17.beta.-[[(5-Oxo-2-imidazolin-2-yl)hydranono]methyl]-5.beta.-androstane-3.beta.,14.beta.-diol
10-Formyl-9,12-dipropylindeno-corrannulene
NEBROSTEROID-N;CHOLESTA-5-EN-3-BETA,7-BETA,19-TRIOL-19-ACETATE
Dimethyl anti-14,anti-19-dibromoundecacyclo[9.9.0.0(1,5).0(2,18).0(3,7).0(6,10).0(8,12).0(11,15).0(13,17).0(16,20)]icosane-syn-4,syn-9-dicarboxylate
2',3',5'-Tris-(O-acetyl)-8-ethyladenosine
[4-acetoxy-5-(6-benzamidopurin-9-yl)-3-(dibromomethylene)tetrahydrofuran-2-yl]methyl benzoate
(3S,4S)-3-acetonyl-4-acetyl-3,8-dihydroxy-2,4-dihydro-1H-anthracene-9,10-dione
6-Azaandrostan-7-one, 6-benzyl-17.beta.-hydroxy-
6,7-Isopropylidenedioxy-5,10,10-trimethyl-tricyclo[6.3.0.0(2,5)]undeca-3-en-9-yl Acetate
| Title | Journal or Book | Year |
|---|---|---|
| Methanocarba Modification of Uracil and Adenine Nucleotides: High Potency of Northern Ring Conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but Not P2Y6 Receptors | Journal of Medicinal Chemistry | 2001 |